Related Experiment Video
Updated: Dec 9, 2025
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Advances in understanding and reducing the burden of severe asthma in children
Mariëlle W Pijnenburg1, Louise Fleming2
1Department of Paediatrics, Division of Respiratory Medicine and Allergology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, Netherlands.
Insights
Severe asthma in children, though rare, requires better management strategies. New biologic therapies targeting type 2 inflammation show promise, but individualized assessment is key for effective treatment of pediatric severe asthma.
Area of Science:
- Pediatric Pulmonology
- Immunology
- Pharmacology
Background:
- Severe asthma in children is a rare but serious condition, often resistant to standard high-dose treatments.
- Despite advances in understanding, severe asthma in children still leads to frequent exacerbations, hospitalizations, and high mortality.
- Current management strategies need improvement to prevent disease progression and reduce morbidity.
Purpose of the Study:
- To review the current understanding of severe pediatric asthma phenotypes and pathophysiology.
- To discuss the potential of emerging biologic therapies targeting type 2 inflammation.
- To highlight the need for individualized assessment and tailored management strategies for severe childhood asthma.
Main Methods:
- Literature review of recent advances in severe pediatric asthma research.
- Analysis of the role of type 2 inflammation in severe asthma.
- Discussion of novel therapeutic approaches, including biologics.
- Exploration of risk stratification and personalized medicine strategies.
Main Results:
- Severe asthma in children is a heterogeneous condition with complex pathophysiology.
- Biologics targeting type 2 inflammation represent a promising therapeutic avenue.
- Detailed patient characterization is essential for selecting appropriate treatments.
- Integrated data sources and risk stratification can optimize management.
Conclusions:
- Effective management of severe pediatric asthma requires a multi-faceted approach, including precise phenotyping.
- Targeted biologic therapies offer new hope for improving outcomes in children with severe asthma.
- Personalized treatment strategies, informed by comprehensive assessment, are crucial for reducing the burden of severe asthma in children.
Abstract:
Severe asthma in children is rare, accounting for only a small proportion of childhood asthma. After addressing modifiable factors such as adherence to treatment, comorbidities, and adverse exposures, children whose disease is not well controlled on high doses of medication form a heterogeneous group of severe asthma phenotypes. Over the past decade, considerable advances have been made in understanding the pathophysiology of severe therapy-resistant asthma in children. However, asthma attacks and hospital admissions are frequent and mortality is still unacceptably high. Strategies to modify the natural history of asthma, prevent severe exacerbations, and prevent lung function decline are needed. Mechanistic studies have led to the development of several biologics targeting type 2 inflammation. This growing pipeline has the potential to reduce the burden of severe asthma; however, detailed assessment and characterisation of each child with seemingly severe asthma is necessary so that the most effective and appropriate management strategy can be implemented. Risk stratification, remote monitoring, and the integration of multiple data sources could help to tailor management for the individual child with severe asthma.
Related Concept Videos
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:24Asthma-III: Symptoms and Complications
Classification of Asthma
01:29Asthma-I: Introduction
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms: